Patents by Inventor Aimesther BETANCOURT

Aimesther BETANCOURT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 11890378
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: February 6, 2024
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • FORMULATIONS OF CALCIUM AND PHOSPHATE FOR ORAL INFLAMMATION
    Publication number: 20230241102
    Abstract: The present invention generally relates to liquid compositions and methods for treating oral inflammation by administering a liquid composition to the oral cavity. The liquid composition is prepared from a powder containing calcium glycerophosphate, one or more sodium phosphate salts, sodium chloride, and optionally sodium bicarbonate and silica. The powder is mixed with a quality of water to form a liquid that is supersaturated with calcium ions and phosphate ions and is essentially free of visible particles and precipitate.
    Type: Application
    Filed: February 24, 2023
    Publication date: August 3, 2023
    Inventors: Bartholomew Weldon, Edward Kobus, Sandryne Dumoulin, Aimesther Betancourt, Patrick Gosselin
  • PHARMACEUTICAL COMPOSITIONS COMPRISING LONAFARNIB AND RITONAVIR
    Publication number: 20230218530
    Abstract: Lonafarnib and ritonavir, or a pharmaceutically acceptable salt thereof, are used in combination to treat HDV infection. In one aspect, amorphous co-precipitates comprising lonafarnib, ritonavir, and a co-polymer are provided.
    Type: Application
    Filed: October 19, 2022
    Publication date: July 13, 2023
    Inventors: Patrick GOSSELIN, Aimesther BETANCOURT
  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20230181470
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: August 29, 2022
    Publication date: June 15, 2023
    Inventors: Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
  • Formulations of calcium and phosphate for oral inflammation
    Patent number: 11590165
    Abstract: The present invention generally relates to liquid compositions and methods for treating oral inflammation by administering a liquid composition to the oral cavity. The liquid composition is prepared from a powder containing calcium glycerophosphate, one or more sodium phosphate salts, sodium chloride, and optionally sodium bicarbonate and silica. The powder is mixed with a quality of water to form a liquid that is supersaturated with calcium ions and phosphate ions and is essentially free of visible particles and precipitate.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: February 28, 2023
    Assignee: BAUSCH HEALTH COMPANIES INC.
    Inventors: Bartholomew Weldon, Edward Kobus, Sandryne Dumoulin, Aimesther Betancourt, Patrick Gosselin
  • Methods of treating hepatitis delta virus infection
    Patent number: 11517532
    Abstract: Lonafarnib and ritonavir, or a pharmaceutically acceptable salt thereof, are used in combination to treat HDV infection. In one aspect, amorphous co-precipitates comprising lonafarnib, ritonavir, and a co-polymer are provided.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: December 6, 2022
    Assignee: Eiger BioPharmaceuticals, Inc.
    Inventors: Patrick Gosselin, Aimesther Betancourt
  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 11471413
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: October 18, 2022
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 11452692
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: September 27, 2022
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO
    Publication number: 20220162160
    Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.
    Type: Application
    Filed: June 25, 2021
    Publication date: May 26, 2022
    Inventors: Stephen Warren Hunt, III, Martin Douglas Phillips, Robert Matunas, Herman Chen, Aimesther Betancourt, Charles Uzarama, Roch Thibert
  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20220151933
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: February 3, 2022
    Publication date: May 19, 2022
    Inventors: Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
  • SOLID ORAL FORMULATIONS OF AMPHOTERICIN B
    Publication number: 20210369615
    Abstract: The present disclosure describes methods of treating infectious diseases with solid dosage forms comprising amphotericin B. In some embodiments, the disclosure provides methods of treating fungal infections and Lesishmania infection.
    Type: Application
    Filed: July 31, 2019
    Publication date: December 2, 2021
    Inventors: Peter HNIK, Roch THIBERT, Aimesther BETANCOURT
  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20210177762
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: January 7, 2021
    Publication date: June 17, 2021
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20210154146
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: February 4, 2021
    Publication date: May 27, 2021
    Inventors: Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
  • PHARMACEUTICAL COMPOSITIONS COMPRISING LONAFARNIB AND RITONAVIR
    Publication number: 20210093571
    Abstract: Lonafarnib and ritonavir, or a pharmaceutically acceptable salt thereof, are used in combination to treat HDV infection. In one aspect, amorphous co-precipitates comprising lonafarnib, ritonavir, and a co-polymer are provided.
    Type: Application
    Filed: October 19, 2020
    Publication date: April 1, 2021
    Applicant: Eiger BioPharmaceuticals, Inc.
    Inventors: PATRICK GOSSELIN, Aimesther Betancourt
  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 10933020
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof, and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: March 2, 2021
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation
    Patent number: 10925832
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: February 23, 2021
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Pharmaceutical compositions comprising lonafarnib and ritonavir
    Patent number: 10835496
    Abstract: Lonafarnib and ritonavir, or a pharmaceutically acceptable salt thereof, are used in combination to treat HDV infection. In one aspect, amorphous co-precipitates comprising lonafarnib, ritonavir, and a co-polymer are provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 17, 2020
    Inventors: Patrick Gosselin, Aimesther Betancourt
  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20200289419
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 17, 2020
    Inventors: Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
  • SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO
    Publication number: 20200255372
    Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.
    Type: Application
    Filed: September 20, 2019
    Publication date: August 13, 2020
    Inventors: Stephen Warren Hunt, III, Martin Douglas Phillips, Robert Matunas, Herman Chen, Aimesther Betancourt, Charles Uzarama, Roch Thibert
  • SOLID ORAL FORMULATIONS OF AMPHOTERICIN B
    Publication number: 20200155583
    Abstract: The present disclosure describes solid dosage forms comprising amphotericin B. Also described herein are methods of treating fungal infections and Lesishmania infections.
    Type: Application
    Filed: February 21, 2018
    Publication date: May 21, 2020
    Inventors: Peter HNIK, Roch THIBERT, Aimesther BETANCOURT